{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T19:30:23Z","timestamp":1668713423786},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T00:00:00Z","timestamp":1474588800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Pierre Fabre Oncologie"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2782-3","type":"journal-article","created":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T07:00:11Z","timestamp":1474614011000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy"],"prefix":"10.1186","volume":"16","author":[{"given":"N.","family":"Hou\u00e9d\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Locker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Soto","family":"Parra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Basso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Spaeth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Tambaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Basterretxea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Theodore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Lusuardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Lainez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Tonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bielle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X. Garcia","family":"Del Muro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,23]]},"reference":[{"key":"2782_CR1","first-page":"31","volume":"10","author":"E Pasin","year":"2008","unstructured":"Pasin E, Josephson DY, Mitra AP, Cote RJ, Stein JP. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol. 2008;10:31\u201343.","journal-title":"Rev Urol"},{"key":"2782_CR2","unstructured":"Muscle-invasive and metastatic bladder cancer - EAU guidelines 2015 [Internet]. http:\/\/uroweb.org\/wp-content\/uploads\/07-Muscle-Invasive-BC_LR.pdf . Accessed 11 July 2016."},{"key":"2782_CR3","unstructured":"Globocan. Table by populations (Incidence\/Mortality) [Internet]. 2012. http:\/\/globocan.iarc.fr\/Pages\/summary_table_site_sel.aspx . Accessed 11 July 2016."},{"key":"2782_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/01.ju.0000162039.38023.5f","volume":"174","author":"JE Rosenberg","year":"2005","unstructured":"Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol. 2005;174:14\u201320.","journal-title":"J Urol"},{"key":"2782_CR5","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/S1040-8428(03)00068-4","volume":"46 Suppl","author":"CN Sternberg","year":"2003","unstructured":"Sternberg CN, Vogelzang NJ. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol. 2003;46 Suppl:S105\u201315.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2782_CR6","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H Maase von der","year":"2005","unstructured":"von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602\u20138.","journal-title":"J Clin Oncol"},{"key":"2782_CR7","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1053\/j.seminoncol.2012.08.007","volume":"39","author":"J Bellmunt","year":"2012","unstructured":"Bellmunt J, Petrylak DP. New therapeutic challenges in advanced bladder cancer. Semin Oncol. 2012;39:598\u2013607.","journal-title":"Semin Oncol"},{"issue":"Suppl 3","key":"2782_CR8","doi-asserted-by":"publisher","first-page":"iii40","DOI":"10.1093\/annonc\/mdu223","volume":"25","author":"J Bellmunt","year":"2014","unstructured":"Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A, et al. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii40\u20138.","journal-title":"Ann Oncol"},{"key":"2782_CR9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/cncr.22031","volume":"107","author":"A Dash","year":"2006","unstructured":"Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107:506\u201313.","journal-title":"Cancer"},{"key":"2782_CR10","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1200\/JCO.2015.65.9797","volume":"34","author":"MI Milowsky","year":"2016","unstructured":"Milowsky MI, Rumble RB, Booth CM, Gilligan T, Eapen LJ, Hauke RJ, et al. Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016;34:1945\u201352.","journal-title":"J Clin Oncol"},{"key":"2782_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66:42\u201354.","journal-title":"Eur Urol"},{"key":"2782_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1200\/JCO.2015.64.1076","volume":"34","author":"MD Galsky","year":"2016","unstructured":"Galsky MD, Stensland KD, Moshier E, Sfakianos JP, McBride RB, Tsao C-K, et al. Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. J Clin Oncol. 2016;34:825\u201332.","journal-title":"J Clin Oncol"},{"key":"2782_CR13","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","volume":"28","author":"J Bellmunt","year":"2010","unstructured":"Bellmunt J, Choueiri TK, Fougeray R, Schutz FAB, Salhi Y, Winquist E, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28:1850\u20135.","journal-title":"J Clin Oncol"},{"key":"2782_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clgc.2011.11.005","volume":"10","author":"G Sonpavde","year":"2012","unstructured":"Sonpavde G, Watson D, Tourtellott M, Cowey CL, Hellerstedt B, Hutson TE, et al. Administration of cisplatin-based chemotherapy for advanced Urothelial carcinoma in the community. Clin Genitourin Cancer. 2012;10:1\u20135.","journal-title":"Clin Genitourin Cancer"},{"key":"2782_CR15","unstructured":"Galsky MD. Treatment patterns and outcomes in \u201creal world\u201d patients (pts) with metastatic urothelial cancer (UC). J Clin Oncol. http:\/\/meetinglibrary.asco.org\/content\/110719-132 . Accessed 11 July 2016."},{"key":"2782_CR16","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H Maase von der","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068\u201377.","journal-title":"J Clin Oncol"},{"key":"2782_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/annonc\/mdv509","volume":"27","author":"D Raggi","year":"2016","unstructured":"Raggi D, Miceli R, Sonpavde G, Giannatempo P, Mariani L, Galsky MD, et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27:49\u201361.","journal-title":"Ann Oncol"},{"key":"2782_CR18","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","volume":"27","author":"J Bellmunt","year":"2009","unstructured":"Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the Urothelial tract. J Clin Oncol. 2009;27:4454\u201361.","journal-title":"J Clin Oncol"},{"key":"2782_CR19","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/annonc\/mdt007","volume":"24","author":"J Bellmunt","year":"2013","unstructured":"Bellmunt J, Fougeray R, Rosenberg JE, von der Maase H, Schutz FA, Salhi Y, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol. 2013;24:1466\u201372.","journal-title":"Ann Oncol"},{"key":"2782_CR20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s12885-015-1434-3","volume":"15","author":"M Retz","year":"2015","unstructured":"Retz M, de Geeter P, Goebell PJ, Matz U, de Schultz W, Hegele A. Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience. BMC Cancer. 2015;15:455.","journal-title":"BMC Cancer"},{"key":"2782_CR21","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1186\/1471-2407-14-779","volume":"14","author":"D Castellano","year":"2014","unstructured":"Castellano D, Puente J, de Velasco G, Chirivella I, L\u00f3pez-Criado P, Mohedano N, et al. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer. 2014;14:779.","journal-title":"BMC Cancer"},{"key":"2782_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/CAD.0000000000000297","volume":"27","author":"N Pistamaltzian","year":"2016","unstructured":"Pistamaltzian N, Tzannis K, Pissanidou V, Peroukidis S, Milaki G, Karavasilis V, et al. Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group. Anticancer Drugs. 2016;27:48\u201353.","journal-title":"Anticancer Drugs"},{"key":"2782_CR23","unstructured":"VICTOR. Vinflunine (Vin) in advanced metastatic transitional cell carcinoma of the urothelium (TCCU)\u2014A retrospective analysis of use of Vin in multicenter, real life setting as second-line chemotherapy (ChT) through free-of charge-programme (FOCP) for patients (pts) in the UK. | 2015. Genitourinary Cancers Symposium | Abstracts | Meeting Library [Internet]. http:\/\/meetinglibrary.asco.org\/content\/141508-159 . Accessed 11 July 2016."},{"key":"2782_CR24","first-page":"e25","volume":"18","author":"FA Yafi","year":"2011","unstructured":"Yafi FA, North S, Kassouf W. First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol Tor Ont. 2011;18:e25\u201334.","journal-title":"Curr Oncol Tor Ont"},{"key":"2782_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1586\/14737140.3.1.11","volume":"3","author":"H Maase von der","year":"2003","unstructured":"von der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther. 2003;3:11\u20139.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2782_CR26","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/annonc\/mdq398","volume":"22","author":"P Albers","year":"2011","unstructured":"Albers P, Park S-I, Niegisch G, Fechner G, Steiner U, Lehmann J, et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20\/99]. Ann Oncol. 2011;22:288\u201394.","journal-title":"Ann Oncol"},{"key":"2782_CR27","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558\u201362.","journal-title":"Nature"},{"key":"2782_CR28","unstructured":"Press Announcements - FDA approves new, targeted treatment for bladder cancer [Internet]. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm501762.htm . Accessed 11 July 2016."},{"key":"2782_CR29","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909\u201320.","journal-title":"Lancet"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2782-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-016-2782-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2782-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T19:33:07Z","timestamp":1498332787000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2782-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,23]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2782"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2782-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,23]]},"article-number":"752"}}